Cell and gene therapy (CGT) includes the injection of cells, genes, or gene-modified cells into a patient with the purpose of preventing or treating a disease. Cell therapy involves the injection of cells to replace or aid the repair of damaged cells, whereas gene therapy involves the injection of genes into cells to alter the genetic makeup of the recipient cells. Cell-based gene therapies, such as chimeric antigen receptor T (CAR-T) therapy, represent combinations of both approaches.

The global Cell Gene Therapy Biomanufacturing market size is projected to grow from US$ 15080 million in 2024 to US$ 28210 million in 2030; it is expected to grow at a CAGR of 11.0% from 2024 to 2030.

ReportPrime's newest research report, the “Cell Gene Therapy Biomanufacturing Industry Forecast” looks at past sales and reviews total world Cell Gene Therapy Biomanufacturing sales in 2022, providing a comprehensive analysis by region and market sector of projected Cell Gene Therapy Biomanufacturing sales for 2023 through 2029. With Cell Gene Therapy Biomanufacturing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cell Gene Therapy Biomanufacturing industry.

This Insight Report provides a comprehensive analysis of the global Cell Gene Therapy Biomanufacturing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Cell Gene Therapy Biomanufacturing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cell Gene Therapy Biomanufacturing market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cell Gene Therapy Biomanufacturing and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cell Gene Therapy Biomanufacturing.

In recent years, the demand for cell and gene therapy (CGT) has surged as the number of United States Food and Drug Administration (U.S. FDA)-approved CGT products has increased annually. This increasing demand underscores the pressing need for manufacturers to improve and advance their production processes to keep pace with the rapidly evolving CGT field. The entire CGT manufacturing process must occur in a facility that complies with good manufacturing practice (GMP) regulations and has received full authorization to manufacture CGTs or advanced-therapy medicinal products, as they are referred to in Europe, for human use. Numerous clinical trials have been conducted to assess the safety and efficacy of CGTs for a wide range of clinical indications, including cancer.

This report presents a comprehensive overview, market shares, and growth opportunities of Cell Gene Therapy Biomanufacturing market by product type, application, key players and key regions and countries.

• Consumables
• Equipment
• Software Solutions

• Life Science Companies
• Contract Research Organizations
• Contract Manufacturing Organizations
• Cell Banks

This report also splits the market by region:

• United States
• Canada
• Mexico
• Brazil

• China
• Japan
• Korea
• Southeast Asia
• India
• Australia

• Germany
• France
• UK
• Italy
• Russia

• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

• Lonza Group
• Thermo Fisher Scientific Inc.
• Merck KGaA
• WuXi AppTec
• Catalent, Inc.
• Samsung Biologics
• FUJIFILM Diosynth Biotechnologies
• Charles River Laboratories
• Cytiva
• Novasep